CVRx (NASDAQ:CVRX) Stock Price Target Lowered at Cantor Fitzgerald

CVRx (NASDAQ:CVRX – Free Report) had its price target trimmed by Cantor Fitzgerald to $2.00 in a report issued on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities analysts have also recently weighed in on CVRX. Wall Street Zen cut CVRx from a “sell” rating to a “strong sell” rating in a research report on Sunday. Canaccord Genuity Group lowered CVRx from a “buy” rating to a “hold” rating and decreased their price objective for the company from $5.00 to $2.00 in a research note on Friday, November 6th. Piper Sandler cut CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a report on Friday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Friday, October 30th. Finally, William Blair downgraded CVRx from an “outperform” rating to a “market perform” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.70.

Read Our Latest Research Report on CVRx

CVRx Price Performance

CVRX opened at $0.61 on Friday. CVRx has a 12 month low of $0.60 and a 12 month high of $10.28. The company has a market cap of $17.30 million, a PE ratio of -0.30 and a beta of 0.81. The company has a current ratio of 6.80, a quick ratio of 5.71 and a debt-to-equity ratio of 4.24. The company has a 50 day moving average of $1.85 and a 200 day moving average of $5.00.

CVRx (NASDAQ:CVRX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The business had revenue of $13.83 million for the quarter, compared to the consensus estimate of $13.93 million. CVRx had a negative net margin of 88.28% and a negative return on equity of 208.45%. On average, sell-side analysts expect that CVRx will post -2.04 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CVRX. Johnson & Johnson purchased a new position in shares of CVRx during the 2nd quarter valued at $20,687,786. BlackRock Inc. bought a new position in shares of CVRx in the second quarter worth $6,402,000. Royal Bank of Canada increased its holdings in shares of CVRx by 6,559.3% in the first quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock worth $6,688,000 after purchasing an additional 696,334 shares during the period. FourWorld Capital Management LLC raised its position in shares of CVRx by 28.9% in the first quarter. FourWorld Capital Management LLC now owns 231,996 shares of the company’s stock worth $2,195,000 after buying an additional 51,996 shares in the last quarter. Finally, First Eagle Investment Management LLC purchased a new stake in shares of CVRx in the third quarter worth $386,000. 75.27% of the stock is owned by institutional investors.

CVRx Company Profile

(Get Free Report)

CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.

See Also

Analyst Recommendations for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.